GREY:IPHAF - Post by User
Post by
snrkidon Jun 05, 2008 8:53am
329 Views
Post# 15147722
Markets and efficacy
Markets and efficacyCalcineurin Inhibitor Market
Tacrolimus is the global market leader in transplant, garnering about 75% of the US calcineurin inhibitor market. Calcineurin inhibitors are a core part of the drug regimen of kidney transplant patients, 93% of whom receive a calcineurin inhibitor. Worldwide, the calcineurin inhibitor market is currently approximately $2.8 billion, and expected to grow to $4 billion by 2010.
Efficacy
In PROMISE, the primary endpoint (biopsy proven acute rejection, BPAR) was clearly met in all three voclosporin dose groups. BPAR is a measure of acute rejection in transplant. In clinical practice, patients with more episodes of BPAR, typically 10-15% at 6 months, have worse outcomes. The results show that voclosporin is as efficacious as tacrolimus, has the dose response expected in a Phase 2 trial, and provides the rationale for dose selection for the Phase 3 clinical program.